A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) (NCT06616974)
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of TX000045 After 24 Weeks of Treatment in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF)
🩺 Plain-English Summary (8th-Grade Level)
TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).
Who can join: Review the eligibility criteria below.
Location: Phoenix — Phoenix, Arizona
Age range: 18 Years to 83 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (72 Sites)
Showing the first 25 of 72 sites.
- Phoenix — Phoenix, Arizona
- Scottsdale — Scottsdale, Arizona
- San Francisco — San Francisco, California
- Santa Rosa — Santa Rosa, California
- Aurora — Aurora, Colorado
- Jacksonville — Jacksonville, Florida
- Augusta — Augusta, Georgia
- McDonough — McDonough, Georgia
- Boise — Boise, Idaho
- USA — Louisville, Kentucky
- Baltimore — Baltimore, Maryland
- Boston — Boston, Massachusetts
- Minneapolis — Minneapolis, Minnesota
- St Louis — St Louis, Missouri
- Omaha — Omaha, Nebraska
- New York — New York, New York
- New York — New York, New York
- Durham — Durham, North Carolina
- Philadelphia — Philadelphia, Pennsylvania
- Pittsburgh — Pittsburgh, Pennsylvania
- York — York, Pennsylvania
- Port Arthur — Port Arthur, Texas
- Waco — Waco, Texas
- Salt Lake City — Salt Lake City, Utah
- United States — Norfolk, Virginia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pulmonary Hypertension
- Trans-pulmonary Biomarkers in Pulmonary Hypertension — Nashville, Tennessee
- Activity Monitoring in Pulmonary Hypertension — Nashville, Tennessee
- LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF — Tucson, Arizona
- A Study of Mosliciguat in PH-ILD — Phoenix, Arizona
- Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD — San Francisco, California
Explore by condition: All Pulmonary Hypertension clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.